OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY
Nearly one million men each year are newly diagnosed with prostate cancer (PCa), making it the fifth most common cancer in both sexes combined and the second most common among men worldwide. In 2014 in the United States alone it is estimated that the disease will culminate in 233,000 new cases and 29,480 deaths. As such, PCa has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

TARGET AUDIENCE
This activity is intended for medical, radiation and surgical oncologists and other healthcare professionals involved in the treatment of breast cancer.

TARGET AUDIENCE
This activity is intended for medical oncologists, urologists and other healthcare professionals involved in the treatment of prostate cancer (PC).

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY
Breast cancer continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY
Taken together, it is estimated that 156,420 new cases of lymphoma, multiple myeloma and leukemia will be identified in the United States in the year 2014, and 55,350 individuals will die of these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastric and pancreatic cancer.